{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=6", "query": { "condition": "Relapsed/Refractory ALL", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3664, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T11:04:16.960Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006213", "title": "BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Promyelocytic Leukemia (M3)", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "BMS-214662", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 30, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006213" }, { "nct_id": "NCT00081874", "title": "RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Mantle Cell Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 29, "start_date": "2004-04", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081874" }, { "nct_id": "NCT05722418", "title": "CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "CB-011", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Caribou Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-02-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722418" }, { "nct_id": "NCT00002865", "title": "High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "low-LET cobalt-60 gamma ray therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "1995-04", "completion_date": "2001-08", "has_results": false, "last_update_posted_date": "2018-08-10", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002865" }, { "nct_id": "NCT03962465", "title": "Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Prednisone Pill", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 36, "start_date": "2022-07-22", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 4, "location_summary": "Nashville, Tennessee • Charlottesville, Virginia • Richmond, Virginia + 1 more", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03962465" }, { "nct_id": "NCT02546167", "title": "CART-BCMA Cells for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CART-BCMA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-09-03", "completion_date": "2020-07-27", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546167" }, { "nct_id": "NCT01647971", "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma", "B-cell Lymphoma", "Waldenstrom's Macroglobulinemia", "Marginal Zone Lymphoma", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2012-07-19", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2022-11-21", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 8, "location_summary": "Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Athens", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01647971" }, { "nct_id": "NCT07586618", "title": "First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Lymphoma", "Acute Lymphoblastic Leukemia ALL" ], "interventions": [ { "name": "4A10", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allterum Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-06-01", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 7, "location_summary": "Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07586618" }, { "nct_id": "NCT01550185", "title": "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "eltrombopag olamine", "type": "DRUG" }, { "name": "standard follow-up care", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Buffalo, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01550185" }, { "nct_id": "NCT01646762", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2012-11-05", "completion_date": "2015-10-27", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-11-04T11:04:16.960Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01646762" } ] }